Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.44 |
| ▸ | HTR1A | P08908 | 10/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3419684 | 0.86 | HTR2C (0.52) | HTR2CADRB2SLC6A4HTR1ASLC6A2 | |
| SCHEMBL3418902 | 0.85 | HTR2C (0.47) | HTR2CADRB2SLC6A4HTR1ASLC6A2 | |
| SCHEMBL3418785 | 0.81 | HTR2C (0.64) | HTR2CADRB2SLC6A4HTR1ASLC6A2 | |
| SCHEMBL3418989 | 0.81 | SLC6A4 (0.44) | HTR2CADRB2SLC6A4HTR1ASLC6A2 | |
| SCHEMBL5387687 | 0.80 | SLC6A4 (0.59) | HTR2CADRB2SLC6A4HTR1ASLC6A2 | |
| SCHEMBL3420383 | 0.77 | HTR2A (0.46) | HTR2CADRB2SLC6A4HTR1ASLC6A2 | |
| SCHEMBL3422165 | 0.77 | IDO1 (0.56) | HTR2CADRB2SLC6A4HTR1ASLC6A2 | |
| SCHEMBL3418567 | 0.76 | HTR2C (0.49) | HTR2CADRB2SLC6A4HTR1ASLC6A2 | |
| SCHEMBL3420354 | 0.76 | HTR1A (0.53) | HTR2CADRB2SLC6A4HTR1AHTR6 | |
| SCHEMBL3538396 | 0.73 | SLC6A2 (0.50) | HTR2CSLC6A4HTR1ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678800-B2 | 2-(1H-indolylsulfanyl)-aryl amine derivatives for use in the treatment of affective disorders, pain, ADHD and stress urinary incontinence | H. LUNDBECK A/S (DK) | 2010-03-16 | — | — | US | claimed |
| EP-1771415-B1 | 2- (1H-INDOLYLSULFANYL) -ARYL AMINE DERIVATIVES FOR USE IN THE TREATMENT OF AFFECTIVE DISORDERS, PAIN, ADHD AND STRESS URINARY INCONTINENCE | LUNDBECK & CO AS H (DK) | 2009-01-07 | — | — | EP | claimed |
| US-20080027074-A1 | 2-(1H-Indolysulfanyl)-Aryl Amine Derivatives for Use in the Treatment of Affective Disorders, Pain, Adhd and Stress Urinary Incontinence | H. LUNDBECK A/S (DK) | 2008-01-31 | — | — | US | claimed |
| US-7678800-B2 | 2-(1H-indolylsulfanyl)-aryl amine derivatives for use in the treatment of affective disorders, pain, ADHD and stress urinary incontinence | H. LUNDBECK A/S (DK) | 2010-03-16 | — | — | US | disclosed |
| EP-1771415-B1 | 2- (1H-INDOLYLSULFANYL) -ARYL AMINE DERIVATIVES FOR USE IN THE TREATMENT OF AFFECTIVE DISORDERS, PAIN, ADHD AND STRESS URINARY INCONTINENCE | LUNDBECK & CO AS H (DK) | 2009-01-07 | — | — | EP | disclosed |
| US-20080027074-A1 | 2-(1H-Indolysulfanyl)-Aryl Amine Derivatives for Use in the Treatment of Affective Disorders, Pain, Adhd and Stress Urinary Incontinence | H. LUNDBECK A/S (DK) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027074-A1 | 2-(1H-Indolysulfanyl)-Aryl Amine Derivatives for Use in the Treatment of Affective Disorders, Pain, Adhd and Stress Urinary Incontinence | SLC6A2, HTR2C, SLC6A3 | HTR2C 2/4885ADRB2 34/4885SLC6A4 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.